Cargando…

Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes

Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central nervous system. It is a heterogeneous pathology that can follow different clinical courses, and the mechanisms that underlie the progression of the immune response across MS subtypes remain incompletely unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Arellano, Gabriel, Acuña, Eric, Reyes, Lilian I., Ottum, Payton A., De Sarno, Patrizia, Villarroel, Luis, Ciampi, Ethel, Uribe-San Martín, Reinaldo, Cárcamo, Claudia, Naves, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491887/
https://www.ncbi.nlm.nih.gov/pubmed/28713377
http://dx.doi.org/10.3389/fimmu.2017.00753
_version_ 1783247211390304256
author Arellano, Gabriel
Acuña, Eric
Reyes, Lilian I.
Ottum, Payton A.
De Sarno, Patrizia
Villarroel, Luis
Ciampi, Ethel
Uribe-San Martín, Reinaldo
Cárcamo, Claudia
Naves, Rodrigo
author_facet Arellano, Gabriel
Acuña, Eric
Reyes, Lilian I.
Ottum, Payton A.
De Sarno, Patrizia
Villarroel, Luis
Ciampi, Ethel
Uribe-San Martín, Reinaldo
Cárcamo, Claudia
Naves, Rodrigo
author_sort Arellano, Gabriel
collection PubMed
description Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central nervous system. It is a heterogeneous pathology that can follow different clinical courses, and the mechanisms that underlie the progression of the immune response across MS subtypes remain incompletely understood. Here, we aimed to determine differences in the immunological status among different MS clinical subtypes. Blood samples from untreated patients diagnosed with clinically isolated syndrome (CIS) (n = 21), different clinical forms of MS (n = 62) [relapsing–remitting (RRMS), secondary progressive, and primary progressive], and healthy controls (HCs) (n = 17) were tested for plasma levels of interferon (IFN)-γ, IL-10, TGF-β, IL-17A, and IL-17F by immunoanalysis. Th1 and Th17 lymphocyte frequencies were determined by flow cytometry. Our results showed that IFN-γ levels and the IFN-γ/IL-10 ratio were higher in CIS patients than in RRMS patients and HC. Th1 cell frequencies were higher in CIS and RRMS than in progressive MS, and RRMS had a higher Th17 frequency than CIS. The Th1/Th17 cell ratio was skewed toward Th1 in CIS compared to MS phenotypes and HC. Receiver operating characteristic statistical analysis determined that IFN-γ, the IFN-γ/IL-10 ratio, Th1 cell frequency, and the Th1/Th17 cell ratio discriminated among CIS and MS subtypes. A subanalysis among patients expressing high IL-17F levels showed that IL-17F and the IFN-γ/IL-17F ratio discriminated between disease subtypes. Overall, our data showed that CIS and MS phenotypes displayed distinct Th1- and Th17-related cytokines and cell profiles and that these immune parameters discriminated between clinical forms. Upon validation, these parameters might be useful as biomarkers to predict disease progression.
format Online
Article
Text
id pubmed-5491887
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54918872017-07-14 Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes Arellano, Gabriel Acuña, Eric Reyes, Lilian I. Ottum, Payton A. De Sarno, Patrizia Villarroel, Luis Ciampi, Ethel Uribe-San Martín, Reinaldo Cárcamo, Claudia Naves, Rodrigo Front Immunol Immunology Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central nervous system. It is a heterogeneous pathology that can follow different clinical courses, and the mechanisms that underlie the progression of the immune response across MS subtypes remain incompletely understood. Here, we aimed to determine differences in the immunological status among different MS clinical subtypes. Blood samples from untreated patients diagnosed with clinically isolated syndrome (CIS) (n = 21), different clinical forms of MS (n = 62) [relapsing–remitting (RRMS), secondary progressive, and primary progressive], and healthy controls (HCs) (n = 17) were tested for plasma levels of interferon (IFN)-γ, IL-10, TGF-β, IL-17A, and IL-17F by immunoanalysis. Th1 and Th17 lymphocyte frequencies were determined by flow cytometry. Our results showed that IFN-γ levels and the IFN-γ/IL-10 ratio were higher in CIS patients than in RRMS patients and HC. Th1 cell frequencies were higher in CIS and RRMS than in progressive MS, and RRMS had a higher Th17 frequency than CIS. The Th1/Th17 cell ratio was skewed toward Th1 in CIS compared to MS phenotypes and HC. Receiver operating characteristic statistical analysis determined that IFN-γ, the IFN-γ/IL-10 ratio, Th1 cell frequency, and the Th1/Th17 cell ratio discriminated among CIS and MS subtypes. A subanalysis among patients expressing high IL-17F levels showed that IL-17F and the IFN-γ/IL-17F ratio discriminated between disease subtypes. Overall, our data showed that CIS and MS phenotypes displayed distinct Th1- and Th17-related cytokines and cell profiles and that these immune parameters discriminated between clinical forms. Upon validation, these parameters might be useful as biomarkers to predict disease progression. Frontiers Media S.A. 2017-06-30 /pmc/articles/PMC5491887/ /pubmed/28713377 http://dx.doi.org/10.3389/fimmu.2017.00753 Text en Copyright © 2017 Arellano, Acuña, Reyes, Ottum, De Sarno, Villarroel, Ciampi, Uribe-San Martín, Cárcamo and Naves. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Arellano, Gabriel
Acuña, Eric
Reyes, Lilian I.
Ottum, Payton A.
De Sarno, Patrizia
Villarroel, Luis
Ciampi, Ethel
Uribe-San Martín, Reinaldo
Cárcamo, Claudia
Naves, Rodrigo
Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
title Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
title_full Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
title_fullStr Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
title_full_unstemmed Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
title_short Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
title_sort th1 and th17 cells and associated cytokines discriminate among clinically isolated syndrome and multiple sclerosis phenotypes
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491887/
https://www.ncbi.nlm.nih.gov/pubmed/28713377
http://dx.doi.org/10.3389/fimmu.2017.00753
work_keys_str_mv AT arellanogabriel th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT acunaeric th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT reyesliliani th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT ottumpaytona th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT desarnopatrizia th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT villarroelluis th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT ciampiethel th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT uribesanmartinreinaldo th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT carcamoclaudia th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes
AT navesrodrigo th1andth17cellsandassociatedcytokinesdiscriminateamongclinicallyisolatedsyndromeandmultiplesclerosisphenotypes